Australia's Top Medical Body Backs Puberty Blockers for Trans Youth, With Conditions
Australia's National Health and Medical Research Council says puberty blockers are appropriate for transgender children in certain cases. The interim guidelines, out Monday, reject the "wait and see" approach and could pressure states that have banned the treatment. Public consultation runs until January 18.
- Original source: theguardian.com.
- The source published it on Nov 16, 2026 at 3:15 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Australia's National Health and Medical Research Council has advised that puberty blockers are appropriate for the gender-affirming care of young people in some circumstances. The council released interim national clinical practice guidelines on Monday recommending conditional use of puberty suppressants for under-18s, following a year-long review of international evidence. The advice could push state and territory governments to reconsider their own positions.
The federal government commissioned the review last year in response to bans on the treatment in Queensland and Northern Territory public hospitals. New Zealand's government later followed suit, despite widespread opposition from the health sector and warnings the bans would harm children. The NHMRC explicitly rejected alternatives proposed by opponents of gender-affirming care, including the so-called wait-and-see model, describing it as withholding care that can affect the young person's physical and mental health, wellbeing, and ability to function.
The guidelines do not require a child to be distressed to be treated for gender incongruence. A multi-disciplinary team should be determined on a case-by-case basis, the advice says, and doctors should prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy. Gender incongruence is the clinical term for a difference between a person's gender and their sex recorded at birth, and it is not a mental health disorder, the guidelines state, though some young people with it also experience significant distress known as gender dysphoria.
Puberty blockers stop the body from producing oestrogen and testosterone. They have been used to treat conditions such as precocious puberty since the 1970s, and in gender-affirming care since the 1990s. The NHMRC, an independent statutory agency funded by the commonwealth and one of the world's largest medical research organisations, says its advice is based on its multidisciplinary gender guideline development committee and supported by a systematic review of the evidence. It largely aligns with AusPATH's Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, the country's only existing guidelines for doctors.
Trans and gender diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care, the review reads. Public consultation on the interim advice, titled Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18, runs until January 18. The full guidelines, which will also cover gender-affirming hormones, are expected in 2028.
TopicsNHMRC · AusPATH · Queensland · Northern Territory · New Zealand
Source: theguardian.com
Written by AI from verified reporting. Not financial advice.
More stories
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status
- Health & science aol.com 1 viewFDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo

